Table 6.

Model-estimated time point probability of immune recovery by the type of cancer adjuvant therapy

	Time point (month)	Chemotherapy Probability	Radiotherapy Probability	Chemo+ Radiotherapy Probability	p
CD4	2	0.45	0.65	0.46	.39
	6	0.45	0.60	0.58	.59
	12	0.18A	0.77B	0.62B	.002
CD56	Combined	0.66	0.70	0.73	.77
CD8	Combined	0.63	0.68	0.59	.66
IFN-r	2	0.33	0.21	0.51	.17
	6	0.25	0.53	0.43	.27
	12	0.23	0.31	0.21	.82
IL-1α	Combined	0.56	0.25	0.33	.10
IL-2	Combined	0.11A	0.73B	0.29A	.004
IL-4	Combined	0.41A	0.09B	0.26A	.002
IL-6	Combined	0.67	0.53	0.56	.56
NK (MV)	Combined	0.27	0.37	0.38	.65
LAK (MV)	2	0.33	0.37	0.24	.54
	6	0.49	0.45	0.45	.66
	12	0.33A	0.50	0.58B	.05
LP (MV)	Combined	0.29	0.37	0.38	.82

Notes. Pairs of treatment group with different letters (e.g., A and B, A and C, B and C) are significantly different at p < .05.

Combined: Collapsed over types of cancer adjuvant therapy, as interaction with time was not statistically significant.

NK: natural killer cell activity. LAK: lymphokine-activated killer cell activity. LP: lymphocyte proliferation. MV: Multivariate model tested.